Navigation Links
Viropro and Oncobiologics Sign Emerging Markets Biosimilars Deal
Date:2/25/2013

ne of biosimilars and next generation biotherapeutics focused on clinically validated targets in the therapeutic areas of oncology, immuno-oncology, and immunology. Formed by a team of leading industry experts from firms such as Eli Lilly, Bristol-Myers Squibb, Amgen, Genentech, Merck and Pfizer, Oncobiologics operates from a state-of-the-art 30,000 sq.ft. R&D facility in Cranbury, NJ. For more information, please visit www.oncobiologics.com

About Viropro Inc.

Viropro specializes in the development and manufacturing of biopharmaceutical drugs.  Alpha Biologics is the manufacturing arm of Viropro, located on the Penang Science Park located in North Malaysia.  Alpha operates a 50,000 sq. ft. state of the art facility designed by Boccard (France). The Alpha facility has undergone a regulatory agency design review and uses a combination of stainless steel and single-use equipment to maximize operational performance for our manufacturing partners. For more detailed information about the company, visit www.viropro.net

Viropro Inc. Safe Harbor Statement

Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward-looking statements". Forward-looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicatin
'/>"/>

SOURCE Oncobiologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncobiologics, Inc. Announces a Collaboration Agreement with XOMA Corporation to Utilize XOMAs Fully Human Antibody Libraries for Their Discovery Platform
2. Oncobiologics Fills Key Leadership Positions and Names Scientific Advisory Board
3. Research and Markets: Biologics in the Emerging Markets: Ripe for Realization of the Commercial Potential - But Hurdles Still to Overcome
4. New Product Launch: Are your Strategies for Emerging Healthcare and Life Sciences Markets Innovative and Structured?
5. Webinar to Discuss Biosimilar Regulatory Guidelines in India and Emerging Markets
6. Intellitech Announces New Micro Pump Promotes Rapid Growth of Emerging BioTech
7. France & Germany Blood Banking Market: Innovative Technologies and Emerging Business Opportunities in New Research Report at ReportsnReports.com
8. Parthenon Identifies Emerging Opportunities in Targeted Payload Cancer Therapeutics
9. In Vitro Diagnostics (IVD) - Emerging Countries (Brazil, Russia, India, China) Opportunity Assessment, Competitive Landscape and Market Forecasts to 2018
10. QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio
11. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2014)... Albany, NY (PRWEB) July 26, 2014 ... 2020 provides key market data on the Canada ... in millions of US dollars, volume (in units) ... segments - High-End Endoscopy Visualization Systems, Mid-Range Endoscopy ... Browse Full Report at http://www.marketresearchreports.biz/analysis/213254 . , ...
(Date:7/25/2014)... July 26, 2014 "Ischemic Stroke ... 2014" provides data on the Ischemic Stroke and ... elemental information and data relating to the clinical ... View full global Ischemic Stroke Research Report 2014 ... overview of the trial numbers and their recruitment ...
(Date:7/25/2014)... OAKS, Calif. , July 25, 2014 ... Board of Directors today declared a $0.61 per share ... will be paid on Sept. 5, 2014, to all ... on Aug. 14, 2014.  About Amgen ... for patients suffering from serious illnesses by discovering, developing, ...
(Date:7/25/2014)... bacteria live in each person,s digestive tract. Scientists believe ... stave off harmful infections, but their role in human ... light on the role of these bacteria, a team ... recently tracked fluctuations in the bacterial populations of two ... in the July 25 issue of the journal ...
Breaking Biology Technology:Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3
... to Take Full Control of the Entire Clinical ... Disclosure - while Adhering to Changing Regulatory Requirements; ... Their Clinical Trial Registration and Results Disclosure ProcessesNEW ... http://www.intrasphere.com ), a leading services ...
... - European Operating Room Nurses Association ... Accepted,for Accreditation , Earlier today, ... has announced it has taken a further step in ... continued,education. , After receiving earlier ...
... Researchers at Eindhoven University of Technology (TU/e) have developed ... the first time they used mechanical forces to control ... in chemistry. This allowed them to initiate chemical reactions ... developing materials capable of repairing themselves under the influence ...
Cached Biology Technology:Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 2Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 3Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 4Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide 2Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide 3Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide 4A molecular ripcord for chemical reactions 2
(Date:7/27/2014)... that nicotine and cotinine, a metabolite of nicotine, can ... in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or NNK is ... ends up in the tobacco smoke. Once inhaled, it ... is activated by a variety of enzymes called Cytochrome ... nicotine can partially interfere with the activation of NNK, ...
(Date:7/27/2014)... wiped them out if it had taken place slightly ... fresh study using up-to-date fossil records and improved analytical ... of the prehistoric creatures, demise, some 66 million years ... years before a 10km-wide asteroid struck what is now ... volcanic activity, changing sea levels and varying temperatures. ...
(Date:7/27/2014)... the largest prevalence studies to date, researchers from the ... for the hepatitis C virus (HCV). Findings published in ... Study of Liver Diseases, indicate that genotype 1 is ... infected of which one-third reside in East Asia. Genotype ... next most prevalent, followed by genotypes 2, 4, 6, ...
Breaking Biology News(10 mins):Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Dinosaurs fell victim to perfect storm of events, study shows 2Hepatitis C virus genotype 1 is most prevalent worldwide 2
... to train workforce, stimulate economy ALEXANDRIA, Va., May 7 ... 2010 budget request, proposing level funding for the Carl ... at $1.3 billion. The Perkins Act is the primary ... that connect education and real-world careers. The Association for ...
... Providers Team Up to Provide High Volume Transaction ... SHORES, Calif. and NEW YORK, May 11 ... Board: CICI), a leading supplier of electronic signature ... industry* and the recognized leader** in biometric signature ...
... and BEIJING, May 20 Validus Technologies Corporation ... they have formed a strategic manufacturing, marketing and ... of One Time Password (OTP) authentication products to ... http://www.newscom.com/cgi-bin/prnh/20081104/AQTU067LOGO )With increasing data breaches, which have created ...
Cached Biology News:Obama Budget Level Funds Career Technical Education 2Obama Budget Level Funds Career Technical Education 3Striata and CIC Launch Integrated eSignature, eDelivery, and eBilling for the Financial Services Industry 2Striata and CIC Launch Integrated eSignature, eDelivery, and eBilling for the Financial Services Industry 3Striata and CIC Launch Integrated eSignature, eDelivery, and eBilling for the Financial Services Industry 4Striata and CIC Launch Integrated eSignature, eDelivery, and eBilling for the Financial Services Industry 5Validus and HierStar Form Strategic Alliance to Offer the First Complete Range of Authentication Products 2Validus and HierStar Form Strategic Alliance to Offer the First Complete Range of Authentication Products 3
... a series of media originally developed at the ... for the large scale propagation of cells from ... used for the growth and maintenance of cell ... viruses in these cell lines. One of the ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Mfr ...
...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. Mfr Desig: ...
Biology Products: